ACTR-087

N/A

Report date: 2025/02/12 20:00:40

Base Information

Drug NameACTR-087

Drug Alias NameViral ACTR + rituximabCD16V41BBCD3zetaCD16V41BBCD3ACTR-087

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUnum Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCogent Biosciences Inc

Active IndicationsN/A

Inactive IndicationsLymphoma

Other Information

ATC CodeN/A